ReproCELL Inc. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
Sales/Revenue
461
567
1,066
1,258
926
Cost of Goods Sold (COGS) incl. D&A
205
291
824
915
780
Gross Income
256
276
243
343
147
SG&A Expense
349
1,017
1,267
1,287
1,172
EBIT
93
741
1,024
944
1,026
Unusual Expense
-
-
810
-
1,347
Non Operating Income/Expense
43
290
150
8
98
Interest Expense
-
-
7
1
1
Pretax Income
133
457
1,979
937
2,282
Income Tax
1
5
18
25
110
Consolidated Net Income
134
452
1,961
912
2,172
Net Income
134
452
1,961
912
2,172
Net Income After Extraordinaries
134
452
1,961
912
2,172
Net Income Available to Common
134
452
1,961
912
2,172
EPS (Basic)
3.08
9.01
36.16
15.68
34.28
Basic Shares Outstanding
44
50
54
58
63
EPS (Diluted)
3.08
9.01
36.16
15.68
34.28
Diluted Shares Outstanding
44
50
54
58
63
EBITDA
83
605
699
689
772
Non-Operating Interest Income
4
7
10
8
4
Equity in Affiliates (Pretax)
-
7
4
9
11

About ReproCELL

View Profile
Address
KDX Shin-Yokohama 381 Building, 9/F
Yokohama Kanagawa 222
Japan
Employees -
Website http://www.reprocell.com
Updated 09/14/2018
ReproCELL Inc. engages in the development of diverse products with an underlying theme that focuses on stem cell technology. It operates through the following business divisions: Induced Pluripotent Stem (iPS)/Embryonic Stem (ES) Cells and Clinical Testing. The Induced Pluripotent Stem (iPS)/Embryonic Stem (ES) Cells division handles the manufacture and sale of research reagents, and the production and evaluation of cells.